Track Viking Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Viking Therapeutics, Inc. VKTX · Stock Open Viking Therapeutics, Inc. in new tab

29.22 USD
EPS
-5.42
P/B
6.24
ROE
-96.37
Beta
0.75
Target Price
95.32 USD
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc.

🧾 Earnings Recap – Q3 2026

Viking’s shares rose 5.9% after earnings, with investors likely responding to progress toward Phase III testing of both injectable and oral VK2735 and positive maintenance-dosing data. The update also highlighted sharply higher R&D spending and a larger quarterly loss as the pipeline advances.

  • Both injectable VK2735 Phase III VANQUISH trials are fully enrolled and advancing; the oral VK2735 SUNRISE Phase III program began earlier in October.
  • In the injectable maintenance study, participants maintained the majority of their initial weight loss after switching to every-other-week or monthly dosing.
  • Third-quarter R&D expense rose to $166.8 million from $90 million a year earlier; G&A increased to $20.3 million from $8.6 million.
  • Quarterly net loss widened to $183.2 million, or $1.55 per share, from $90.8 million, or $0.81 per share.
  • Viking reported $960 million in cash, cash equivalents and short-term investments at September 30, including net proceeds from recent financing; it expects to complete the VK3019 Phase I single-ascending-dose study by year-end.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 10, 2027
EPS-5.42
Book Value4.62
Price to Book6.24
Debt/Equity43.27
% Insiders2.831%
Estimates
Forward P/E-5.53
Forward EPS-5.21
Target Mean Price95.32

DCF valuation

Model fair value for Viking Therapeutics, Inc. (VKTX)
Result
Sign in to run the valuation for VKTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
19 analysts · consensus Strong buy · mean target 95.32 USD (low 34.00, high 125.00) · as of 10 Nov 2026
Low 34.00
Mean 95.32
High 125.00
Price 29.22
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Viking Therapeutics, Inc. Logo Viking Therapeutics, Inc. Analysis (VKTX)

United States Health Care Official Website Stock

Is Viking Therapeutics, Inc. a good investment? Viking Therapeutics, Inc. (VKTX) is currently trading at 29.22 USD. Market analysts have a consensus price target of 95.32 USD. This suggests a potential upside from current levels.

Earnings Schedule: Viking Therapeutics, Inc. is expected to release its next earnings report on Feb. 10, 2027. The market consensus estimate for Forward EPS is -5.21.

Investor FAQ

Does Viking Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Viking Therapeutics, Inc.?

Viking Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 10, 2027. The company currently has a trailing EPS of -5.42.

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Exchange Ticker
NCM (Australia) VKTX
FRA (Germany) 1VT.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion